Research on type 2 diabetes and its management. Covers nerve pain, early onset, BMI trajectories, and treatment side effects.
A new review suggests that continuous glucose monitoring technology offers no scientific evidence of improved health outcomes in people without diabetes. However, it may be beneficial for those with type 2 diabetes by reducing HbA1c levels and minimizing finger-stick tests.
A new online test, MEDWACS, can detect people with prediabetes or undiagnosed type 2 diabetes with high accuracy. The test measures seven parameters, including thigh length, which is linked to a person's risk of developing the condition.
A study at USC discovers a common genetic variant in Indigenous American populations that silences the microprotein MENTSH, restoring it improves insulin signaling and blocks diet-induced weight gain. MENTSH-based therapies could offer a precision-medicine approach to Type 2 diabetes.
A 16-week personalized exercise intervention improved glycemic regulation, physical fitness and reduced abdominal fat while increasing skeletal muscle mass. Cognitive impairment also showed significant improvements in working memory, perceptual speed and executive function.
A new analysis of 19 randomized controlled trials found that different GLP-1 medications have distinct effects on heart and metabolic health, suggesting a need for personalized treatment selection. Oral GLP-1 therapies are emerging as strong options that could expand accessibility and flexibility.
Researchers have identified transmembrane 4 L six family member 1 (TM4SF1) as a highly selective surface marker of senescent β-cells in both mice and humans. This discovery provides an important step toward developing targeted senotherapies that could preserve insulin secretion and slow the progression of type 2 diabetes.
A new study in the Canadian Journal of Cardiology predicts that generic semaglutide will dramatically increase cost-effectiveness and health system affordability for patients with type 2 diabetes and high cardiorenal risk. The estimated annual cost of providing GLP-1RAs to all indicated patients would be $3.35 to $5.31 billion at pre-g...
Researchers from Rutgers University analyzed US insurance claims data to compare the risk of ischemic optic neuropathy among initiators of GLP-1 RAs versus SGLT-2is or DPP-4is. A small increase in risk was observed, but absolute risk remained very low.
A large Swedish study found that certain bacteria in the gut microbiota can be seen in people who develop type 2 diabetes years later. Fluctuations in metabolism and low fibre intake may also contribute to the risk. The discovery paves the way for early identification of at-risk individuals.
A new study found that GLP-1 receptor agonists can improve long-term health for people with peripheral artery disease (PAD), managing blood sugar and weight loss while reducing inflammation and improving blood vessel function. The benefits were highest among participants with severe PAD and obesity.
Researchers present a roadmap for developing Tregs as adaptable therapies to restore immune balance and support tissue repair. This approach holds promise for treating conditions such as metabolic and cardiovascular disease, as well as neurodegeneration.
New therapies using regulatory T cells, known as Tregs, could target diseases with inflammation, such as cancer and autoimmune conditions. Early evaluations show good tolerance and safety profiles, but precision is key to tailoring treatments for specific patients.
A new study published in Cell Metabolism found that a low-protein, amino acid-supplemented 'longevity diet' improved cardiometabolic markers and reduced frailty and fat mass in mice. The diet was associated with longer healthy lifespan and better metabolic health in both mice and humans.
Researchers at the University of Zurich have developed epigenetic drugs that can reprogram perivascular fat cells to reduce inflammation and improve blood vessel health. By targeting specific gene-expression regulators, these drugs aim to prevent vascular damage in people with obesity and metabolic disease.
A study presented at ENDO 2026 found semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications. The results suggest that semaglutide may have beneficial effects on bone health in people with type 2 diabetes.
A study found that testosterone alone is not enough to prevent type 2 diabetes in older men; lifestyle interventions are crucial for improving blood sugar control and reducing obesity. Testosterone treatment can improve body composition and sexual desire, but its benefits diminish over time.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that enhancing protein-folding processes can help prevent harm to insulin-producing cells. The study revealed the importance of a chaperone protein called binding immunoglobulin protein and its cochaperone protein p58 IPK in maintaining proper proinsulin folding.
A reduction in visceral fat is associated with better cardiometabolic health and lower future type 2 diabetes risk, even when body weight is fully regained. Visceral fat loss achieves a significant protective effect against systemic aging and metabolic decay long after a diet ends.
Researchers at UVA are testing the SIPsmarter program to reduce sugary drink consumption among children and their parents. The study aims to improve beverage quality and overall health outcomes in rural areas with high rates of sugary drink consumption.
Persons with diabetes are at higher risk of periodontitis, tooth loss, and peri-implantitis. Poor blood sugar control exacerbates these risks, highlighting the importance of close collaboration between healthcare and dental care providers.
A study analyzing insurance claims data found similar risks between continued and non-continued GLP-1RA medication use during early pregnancy. The authors conclude that further research is needed to better understand the safety of GLP-1RAs in pregnancy due to imprecise estimates for rare outcomes.
A new study found that U.S. military veterans with both insomnia and obstructive sleep apnea have a substantially elevated risk of developing type 2 diabetes compared to those with either condition alone. The risk is particularly high among younger veterans, even after accounting for demographic and metabolic factors.
A new oral GLP-1 medication, elecoglipron, has been shown to significantly reduce blood glucose levels and bodyweight in adults with type 2 diabetes. The study found that up to 89.6% of participants achieved an HbA1c level of 7%, while 72.3% experienced at least 5% weight reduction.
Researchers found dapagliflozin significantly reduces risk of heart failure hospitalization in individuals carrying a cardiomyopathy genetic variant. The study, published in Nature Medicine, highlights the potential for incorporating genetic screening into heart failure prevention strategies.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
A study found that adding orfglipron to titrated insulin glargine significantly improved glycemic control and body weight in participants with type 2 diabetes. The treatment did not increase the risk of hypoglycemia, compared to placebo.
A major study finds people with diabetes are at higher risk of infection, which can lead to hospitalization and death. The researchers argue that infection prevention and management should be embedded in diabetes guidelines to improve patient outcomes.
Recent studies show finerenone preserves kidney function, reduces cardiovascular risk and improves survival across a broader range of CKD patients. Finerenone also reduces kidney failure, heart failure or cardiovascular death risk by 23-24% in non-diabetic patients.
A new study found that dihydropyridine calcium-channel blockers (DCCBs) may be associated with poorer kidney outcomes in people with type 2 diabetes, even among those receiving modern kidney-protective treatments. DCCBs were linked to a higher risk of major adverse kidney events.
Researchers from Pennington Biomedical will showcase their latest findings on prevention, care, and cures for diabetes and obesity at the American Diabetes Association's 2026 Scientific Sessions. The sessions will highlight cutting-edge advancements driving progress in diabetes research and management.
A new study reveals how Philip Morris Companies Inc. used cigarette research and flavor engineering to design Lunchables, a successful ultra-processed food for children. The company's strategy was based on optimizing 'technical synergies' between tobacco and food divisions.
The FLOW trial shows that semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease. Health utility scores and self-rated general health scores improved with semaglutide, but declined with placebo.
The study found that participants in the 'Healthy Living' online program experienced moderate improvements in their blood sugar levels, blood pressure, and body mass index (BMI). The program was designed to support self-management of type 2 diabetes and showed promising results in England.
A new model predicts retinal degeneration in diabetics based on 71 plasma proteins. The Pro-DRN model can help doctors identify patients at risk earlier, potentially preventing neurodegeneration and vision loss.
Weight loss after bariatric surgery is associated with better ability to cope with daily household tasks such as cleaning and grocery shopping. The study also found that maintaining weight loss for long periods results in improved functionality and independence. Patients who regained lost weight experienced poorer outcomes over time.
A nationally representative study found a nearly 4-fold increase in type 2 diabetes prevalence among US children and adolescents between 10 to 17 years old. The substantial rise is concerning due to the disease's lifetime risk of severe complications and premature deaths.
Research finds gestational diabetes significantly increases risk of type 2 diabetes in women with normal pre-pregnancy weight. The study, published in eClinicalMedicine, analyzed over 1.15 million Swedish mothers and found elevated blood sugar levels predict future type 2 diabetes.
A new study by UMass Amherst researchers found that lifestyle factors such as body weight, physical activity, and diet play a powerful role in shaping diabetes risk. More than half of new Type 2 diabetes cases could be prevented if people with less healthy lifestyles improve those behaviors.
Researchers are developing a multi-organ model on a chip to study the complex interactions between organs, hormones, and cells in diabetes and dementia. The GlucoBrain project aims to understand how signals move between the brain, gut, and pancreas, potentially leading to new treatments for millions affected by these diseases.
Weight loss followed by weight regain, known as 'yo-yo dieting,' is not supported by strong scientific evidence. The authors found that benefits of losing weight outweigh the theoretical risks of weight cycling in most cases. Repeated attempts at weight loss can provide meaningful periods of improved metabolic health and quality of life.
A nationwide self-controlled cohort study found that GLP-1 class of obesity drugs were associated with a 26% fall in asthma exacerbations and a 14% drop in use of asthma inhaler reliever. The study suggests that weight loss, modulation of airway inflammation, and improvements in metabolic functions may improve asthma outcomes.
Researchers have identified potential mechanisms linked to reduced type 2 diabetes risk in chronic cannabis users. A team led by Nicholas V. DiPatrizio found that specific compounds within cannabis regulate metabolism, leading to significant weight loss and improved glucose regulation in obese mice.
A new international study found that genetic variations in the PAM gene can reduce the effectiveness of GLP-1 receptor medications, such as Ozempic. Researchers discovered that 44% of people with these genetic variants experienced reduced glucose lowering properties, and only 11% achieved recommended glucose levels.
A large-scale Nordic study found a link between PCOS and heart disease, with women at increased risk even in normal weight. The study also highlighted the importance of regular medical screenings for women with PCOS.
A new Northwestern University study finds metformin primarily targets the gut, driving glucose utilization inside cells lining the intestine to prevent blood sugar levels from rising. The drug slows mitochondrial energy production in gut cells, allowing the intestine to metabolize extra sugar and regulate blood sugar levels.
The ECE 2026 brings together researchers and clinicians to share the latest endocrine research and developments. Key sessions include Plenaries, Symposia, Awards, Meet the Experts, Debates, and Oral Communications.
A new study has found that individuals with insulin-requiring type 1 and type 2 diabetes have a significantly higher risk of developing dementia compared to those without diabetes. The study, which examined over 1.3 million adults in South Korea, suggests that dementia risk is not the same for all types of diabetes.
A study by the University of Gothenburg reveals that changes in gut bacteria composition after bariatric surgery are strongly associated with improved glucose metabolism and insulin release. Patients with type 2 diabetes who achieved improved glycemic control exhibited greater microbial gene richness and enhanced fermentation processes.
Researchers at Kyoto University discovered that ATF6α plays a critical role in enabling the survival and proliferation of beta cells under sustained stress, leading to impaired beta cell mass expansion. The study highlights the potential for developing new therapeutic strategies to preserve and restore beta cell mass in diabetes.
A $10 million grant from the National Institute of Environmental Health Sciences will support research on PFAS health effects and translate discoveries into real-world solutions. The study aims to identify links between PFAS exposure and metabolic conditions, such as obesity and type 2 diabetes.
A new review found that GLP-1 weight-loss drugs significantly reduced the risk of heart attacks, strokes, and premature death. The treatment also lowered rates of non-fatal heart attacks, hospital admissions for heart failure, and deaths from any cause.
A new approach for treating obesity and type 2 diabetes has been developed using a hybrid molecule that targets specific cells. The treatment combines the well-known GLP-1/GIP signalling pathway with an additional metabolic modulator, delivering improved blood-glucose values and weight loss.
Researchers mapped epigenome changes in cells that regulate blood sugar levels, finding patterns differ between people with and without type 2 diabetes. Epigenetic alterations impact insulin-producing beta cells, leading to impaired energy production and reduced insulin release.
The European Society of Endocrinology organizes World Hormone Day to educate the public about hormone-related health issues. Global endocrine disorders affect millions worldwide, emphasizing the need for proper hormone balance.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population. Obesity was identified as the strongest independent MRF among Asians, Whites, and Hispanics, particularly in individuals younger than 50 years, whereas hypertension was the strongest independent MRF in Blacks.
A major clinical trial found that real-time continuous glucose monitoring significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin. Participants using CGM showed greater reductions in HbA1c levels compared to traditional finger prick glucose monitoring.
A study of 3,000 Punjabi Sikhs identified new molecular pathways contributing to cardiovascular disease, including a link between lipid metabolites and immune cell signaling. These findings offer insights into diverse molecular origins of cardiometabolic disease and potential pathways for designing innovative therapies.
A ketogenic diet has been shown to improve beta-cell function in patients with type 2 diabetes by decreasing proinsulin secretion and reducing pancreas stress. This improvement is associated with changes in the proinsulin-C-peptide ratio, a biomarker of pancreas stress.
A recent study from The Jackson Laboratory has identified dozens of unexpected genes strongly linked to type 2 diabetes. These genes are key to cell death and vitamin A metabolism, suggesting the disease depends on expression changes that can be targeted for treatment.
A massive genetic study has uncovered six new genes linked to pregnancy sickness, hyperemesis gravidarum (HG), in over 10,000 women. The findings point to biological mechanisms behind HG and potential new treatment pathways, with several medications identified as potential targets.